Robert E Landry Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert E Landry.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert E Landry. Robert E Landry is EVP Finance CFO in REGENERON PHARMACEUTICALS, INC. ($REGN) and SVP Fin, Dep CFO in REGENERON PHARMACEUTICALS INC ($REGN) and SVP Finance & CFO in REGENERON PHARMACEUTICALS INC ($REGN).
Latest Insider Trading Transactions of Robert E Landry
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | A | 492.00 | 19,950 | 9,815,400 | 19,950 | |
Dec 11 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Grant | A | 0.00 | 1,930 | 0 | 25,903 | 24 K to 25.9 K (+8.05 %) |
Aug 05 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 654.46 | 696 | 455,504 | 23,973 | 24.7 K to 24 K (-2.82 %) |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 555.67 | 5,000 | 2,778,350 | 5,000 | |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 399.66 | 3,500 | 1,398,810 | 25,000 | |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 658.00 | 3 | 1,974 | 24,669 | 24.7 K to 24.7 K (-0.01 %) |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 647.50 | 388 | 251,230 | 24,672 | 25.1 K to 24.7 K (-1.55 %) |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 655.57 | 4,611 | 3,022,833 | 25,060 | 29.7 K to 25.1 K (-15.54 %) |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 555.67 | 5,000 | 2,778,350 | 29,671 | 24.7 K to 29.7 K (+20.27 %) |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 655.57 | 2,802 | 1,836,907 | 24,671 | 27.5 K to 24.7 K (-10.20 %) |
Jul 22 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 399.66 | 3,500 | 1,398,810 | 27,473 | 24 K to 27.5 K (+14.60 %) |
Jul 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 640.50 | 579 | 370,850 | 23,973 | 24.6 K to 24 K (-2.36 %) |
Jul 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 399.66 | 3,000 | 1,198,980 | 28,500 | |
Jul 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 642.46 | 2,421 | 1,555,396 | 24,552 | 27 K to 24.6 K (-8.98 %) |
Jul 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 399.66 | 3,000 | 1,198,980 | 26,973 | 24 K to 27 K (+12.51 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 555.67 | 10,000 | 5,556,700 | 10,000 | |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 399.66 | 2,500 | 999,150 | 31,500 | |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 650.41 | 3 | 1,951 | 23,973 | 24 K to 24 K (-0.01 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 648.54 | 94 | 60,963 | 23,976 | 24.1 K to 24 K (-0.39 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 646.18 | 37 | 23,909 | 24,070 | 24.1 K to 24.1 K (-0.15 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 645.99 | 57 | 36,821 | 24,107 | 24.2 K to 24.1 K (-0.24 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 643.84 | 104 | 66,959 | 24,164 | 24.3 K to 24.2 K (-0.43 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 642.93 | 48 | 30,861 | 24,268 | 24.3 K to 24.3 K (-0.20 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 640.32 | 43 | 27,534 | 24,316 | 24.4 K to 24.3 K (-0.18 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 639.88 | 80 | 51,190 | 24,359 | 24.4 K to 24.4 K (-0.33 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 638.99 | 45 | 28,755 | 24,439 | 24.5 K to 24.4 K (-0.18 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 637.40 | 40 | 25,496 | 24,484 | 24.5 K to 24.5 K (-0.16 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 636.50 | 585 | 372,353 | 24,524 | 25.1 K to 24.5 K (-2.33 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 634.14 | 24 | 15,219 | 25,109 | 25.1 K to 25.1 K (-0.10 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 640.88 | 2,019 | 1,293,937 | 25,133 | 27.2 K to 25.1 K (-7.44 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 399.66 | 2,500 | 999,150 | 27,152 | 24.7 K to 27.2 K (+10.14 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 640.88 | 9,321 | 5,973,642 | 24,652 | 34 K to 24.7 K (-27.44 %) |
Jul 09 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 555.67 | 10,000 | 5,556,700 | 33,973 | 24 K to 34 K (+41.71 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 616.67 | 31 | 19,117 | 23,973 | 24 K to 24 K (-0.13 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 614.64 | 69 | 42,410 | 24,004 | 24.1 K to 24 K (-0.29 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 612.67 | 153 | 93,739 | 24,073 | 24.2 K to 24.1 K (-0.63 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 611.44 | 50 | 30,572 | 24,226 | 24.3 K to 24.2 K (-0.21 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 610.73 | 58 | 35,422 | 24,276 | 24.3 K to 24.3 K (-0.24 %) |
Jun 30 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 609.46 | 39 | 23,769 | 24,334 | 24.4 K to 24.3 K (-0.16 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 555.67 | 8,900 | 4,945,463 | 20,000 | |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 635.24 | 46 | 29,221 | 24,373 | 24.4 K to 24.4 K (-0.19 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 634.63 | 89 | 56,482 | 24,419 | 24.5 K to 24.4 K (-0.36 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 633.56 | 82 | 51,952 | 24,508 | 24.6 K to 24.5 K (-0.33 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 631.25 | 78 | 49,238 | 24,590 | 24.7 K to 24.6 K (-0.32 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 630.84 | 82 | 51,729 | 24,668 | 24.8 K to 24.7 K (-0.33 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 628.64 | 39 | 24,517 | 24,750 | 24.8 K to 24.8 K (-0.16 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 626.56 | 56 | 35,087 | 24,789 | 24.8 K to 24.8 K (-0.23 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 624.65 | 40 | 24,986 | 24,845 | 24.9 K to 24.8 K (-0.16 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 626.19 | 8,388 | 5,252,482 | 24,885 | 33.3 K to 24.9 K (-25.21 %) |
Jun 24 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 555.67 | 8,900 | 4,945,463 | 33,273 | 24.4 K to 33.3 K (+36.52 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 0 | |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 624.56 | 59 | 36,849 | 24,373 | 24.4 K to 24.4 K (-0.24 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 621.56 | 16 | 9,945 | 24,432 | 24.4 K to 24.4 K (-0.07 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 620.70 | 58 | 36,001 | 24,448 | 24.5 K to 24.4 K (-0.24 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 619.73 | 66 | 40,902 | 24,506 | 24.6 K to 24.5 K (-0.27 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 616.00 | 31 | 19,096 | 24,572 | 24.6 K to 24.6 K (-0.13 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 614.41 | 34 | 20,890 | 24,603 | 24.6 K to 24.6 K (-0.14 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 613.53 | 23 | 14,111 | 24,637 | 24.7 K to 24.6 K (-0.09 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 612.74 | 177 | 108,455 | 24,660 | 24.8 K to 24.7 K (-0.71 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 611.82 | 14 | 8,565 | 24,837 | 24.9 K to 24.8 K (-0.06 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 608.91 | 65 | 39,579 | 24,851 | 24.9 K to 24.9 K (-0.26 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 607.50 | 445 | 270,338 | 24,916 | 25.4 K to 24.9 K (-1.75 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 610.18 | 2,512 | 1,532,772 | 25,361 | 27.9 K to 25.4 K (-9.01 %) |
Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 3,500 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,250 | 613,575 | 5,000 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,250 | 613,575 | 7,250 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 9,500 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 12,000 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 15,500 | |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 610.25 | 527 | 321,602 | 24,373 | 24.9 K to 24.4 K (-2.12 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 609.53 | 681 | 415,090 | 24,900 | 25.6 K to 24.9 K (-2.66 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 608.50 | 1,511 | 919,444 | 25,581 | 27.1 K to 25.6 K (-5.58 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 607.47 | 619 | 376,024 | 27,092 | 27.7 K to 27.1 K (-2.23 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 606.79 | 353 | 214,197 | 27,711 | 28.1 K to 27.7 K (-1.26 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 605.14 | 289 | 174,885 | 28,064 | 28.4 K to 28.1 K (-1.02 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 604.14 | 50 | 30,207 | 28,353 | 28.4 K to 28.4 K (-0.18 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 603.68 | 131 | 79,082 | 28,403 | 28.5 K to 28.4 K (-0.46 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 602.38 | 110 | 66,262 | 28,534 | 28.6 K to 28.5 K (-0.38 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 1,086 | 643,379 | 28,644 | 29.7 K to 28.6 K (-3.65 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 29,730 | 28.2 K to 29.7 K (+5.31 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 1,630 | 965,661 | 28,230 | 29.9 K to 28.2 K (-5.46 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,250 | 613,575 | 29,860 | 27.6 K to 29.9 K (+8.15 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 1,630 | 965,661 | 27,610 | 29.2 K to 27.6 K (-5.57 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,250 | 613,575 | 29,240 | 27 K to 29.2 K (+8.34 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.40 | 1,811 | 1,072,836 | 26,990 | 28.8 K to 27 K (-6.29 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 28,801 | 26.3 K to 28.8 K (+9.51 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 2,536 | 1,502,402 | 26,301 | 28.8 K to 26.3 K (-8.79 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 28,837 | 25.3 K to 28.8 K (+13.81 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 2,536 | 1,502,402 | 25,337 | 27.9 K to 25.3 K (-9.10 %) |
Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 12,500 | 3,408,750 | 19,000 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 31,500 | |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 573.40 | 320 | 183,488 | 24,373 | 24.7 K to 24.4 K (-1.30 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 572.42 | 64 | 36,635 | 24,693 | 24.8 K to 24.7 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 571.65 | 114 | 65,168 | 24,757 | 24.9 K to 24.8 K (-0.46 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 569.22 | 66 | 37,569 | 24,871 | 24.9 K to 24.9 K (-0.26 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 568.11 | 126 | 71,582 | 24,937 | 25.1 K to 24.9 K (-0.50 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 567.76 | 114 | 64,725 | 25,063 | 25.2 K to 25.1 K (-0.45 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 566.44 | 944 | 534,719 | 25,177 | 26.1 K to 25.2 K (-3.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.52 | 902 | 510,099 | 26,121 | 27 K to 26.1 K (-3.34 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 564.76 | 340 | 192,018 | 27,023 | 27.4 K to 27 K (-1.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.74 | 225 | 126,842 | 27,363 | 27.6 K to 27.4 K (-0.82 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.71 | 35 | 19,695 | 27,588 | 27.6 K to 27.6 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 555.82 | 9,250 | 5,141,335 | 27,623 | 36.9 K to 27.6 K (-25.09 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 12,500 | 3,408,750 | 36,873 | 24.4 K to 36.9 K (+51.29 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 565.77 | 44 | 24,894 | 24,373 | 24.4 K to 24.4 K (-0.18 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 563.63 | 66 | 37,200 | 24,417 | 24.5 K to 24.4 K (-0.27 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 562.77 | 33 | 18,571 | 24,483 | 24.5 K to 24.5 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 561.96 | 92 | 51,700 | 24,516 | 24.6 K to 24.5 K (-0.37 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 560.31 | 232 | 129,992 | 24,608 | 24.8 K to 24.6 K (-0.93 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 559.25 | 155 | 86,684 | 24,840 | 25 K to 24.8 K (-0.62 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 558.63 | 89 | 49,718 | 24,995 | 25.1 K to 25 K (-0.35 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 556.43 | 33 | 18,362 | 25,084 | 25.1 K to 25.1 K (-0.13 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 553.85 | 62 | 34,339 | 25,117 | 25.2 K to 25.1 K (-0.25 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 551.38 | 55 | 30,326 | 25,179 | 25.2 K to 25.2 K (-0.22 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 550.00 | 3 | 1,650 | 25,234 | 25.2 K to 25.2 K (-0.01 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 548.99 | 61 | 33,488 | 25,237 | 25.3 K to 25.2 K (-0.24 %) |
Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 542.25 | 33 | 17,894 | 25,298 | 25.3 K to 25.3 K (-0.13 %) |